{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:43:50Z","timestamp":1784234630648,"version":"3.55.0"},"reference-count":261,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.4158\/cs-2017-0153","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T14:51:06Z","timestamp":1516200666000},"page":"91-121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":385,"title":["Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm \u2013 2018 Executive Summary"],"prefix":"10.1016","volume":"24","author":[{"given":"Alan J.","family":"Garber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Abrahamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua I.","family":"Barzilay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Blonde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zachary T.","family":"Bloomgarden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Dagogo-Jack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph A.","family":"DeFronzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Einhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian A.","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Garber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Timothy","family":"Garvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Grunberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yehuda","family":"Handelsman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irl B.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Jellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet B.","family":"McGill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Mechanick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Rosenblit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo E.","family":"Umpierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4158\/CS-2017-0153_bb0010","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"10.4158\/CS-2017-0153_bb0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP15672.GLSUPPL","article-title":"American association of clinical endocrinologists and american college of endocrinology: Clinical practice guidelines for developing a diabetes mellitus comprehensive care plan--2015","volume":"21","author":"Handelsman","year":"2015","journal-title":"Endocr Pract"},{"key":"10.4158\/CS-2017-0153_bb0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/oby.2008.637","article-title":"One-year weight losses in the look ahead study: Factors associated with success","volume":"17","author":"Wadden","year":"2009","journal-title":"Obesity (Silver Spring)"},{"key":"10.4158\/CS-2017-0153_bb0025","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.2337\/dc07-0048","article-title":"Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: One-year results of the look ahead trial","volume":"30","author":"Look AHEAD Research Group","year":"2007","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0030","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2337\/diacare.28.4.888","article-title":"Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program","volume":"28","author":"Ratner","year":"2005","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0035","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s13668-014-0094-2","article-title":"Prevention of diabetes through the lifestyle intervention: Lessons learned from the diabetes prevention program and outcomes study and its translation to practice","volume":"3","author":"Hoskin","year":"2014","journal-title":"Curr Nutr Rep"},{"key":"10.4158\/CS-2017-0153_bb0040","doi-asserted-by":"crossref","first-page":"3821","DOI":"10.2337\/dc13-2042","article-title":"Nutrition therapy recommendations for the management of adults with diabetes","volume":"36","author":"Evert","year":"2013","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0045","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.2337\/dc07-2137","article-title":"Adjust to target in type 2 diabetes: Comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine","volume":"31","author":"Bergenstal","year":"2008","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0050","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/918571","article-title":"Meal replacements for weight loss in type 2 diabetes in a community setting","volume":"2012","author":"Keogh","year":"2012","journal-title":"J Nutr Metab"},{"key":"10.4158\/CS-2017-0153_bb0055","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/ajcn\/69.2.198","article-title":"Metabolic and weight-loss effects of a long-term dietary intervention in obese patients","volume":"69","author":"Ditschuneit","year":"1999","journal-title":"Am J Clin Nutr"},{"key":"10.4158\/CS-2017-0153_bb0060","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/oby.2000.48","article-title":"Metabolic and weight loss effects of long-term dietary intervention in obese patients: Four-year results","volume":"8","author":"Flechtner-Mors","year":"2000","journal-title":"Obes Res"},{"key":"10.4158\/CS-2017-0153_bb0065","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1037\/0022-006X.67.2.260","article-title":"Behavioral choice treatment promotes continuing weight loss: Preliminary results of a cognitive-behavioral decision-based treatment for obesity","volume":"67","author":"Sbrocco","year":"1999","journal-title":"J Consult Clin Psychol"},{"key":"10.4158\/CS-2017-0153_bb0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0306-4603(97)00016-6","article-title":"Effects of a personalized system of skill acquisition and an educational program in the treatment of obesity","volume":"23","author":"Fuller","year":"1998","journal-title":"Addict Behav"},{"key":"10.4158\/CS-2017-0153_bb0075","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1037\/0022-006X.64.1.172","article-title":"An evaluation of a television-delivered behavioral weight loss program: Are the ratings acceptable?","volume":"64","author":"Meyers","year":"1996","journal-title":"J Consult Clin Psychol"},{"key":"10.4158\/CS-2017-0153_bb0080","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1037\/0022-006X.56.4.529","article-title":"Effects of four maintenance programs on the long-term management of obesity","volume":"56","author":"Perri","year":"1988","journal-title":"J Consult Clin Psychol"},{"key":"10.4158\/CS-2017-0153_bb0085","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1001\/archinte.160.14.2150","article-title":"A randomized trial of improved weight loss with a prepared meal plan in overweight and obese patients: Impact on cardiovascular risk reduction","volume":"160","author":"Metz","year":"2000","journal-title":"Arch Intern Med"},{"issue":"Suppl 3","key":"10.4158\/CS-2017-0153_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP13155.GL","volume":"19","author":"Gonzalez-Campoy","year":"2013","journal-title":"Endocr Pract"},{"key":"10.4158\/CS-2017-0153_bb0095","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.2337\/dc06-2495","article-title":"Effects of different modes of exercise training on glucose control and risk factors for complications in type 2 diabetic patients: A meta-analysis: Response to snowling and hopkins","volume":"30","author":"Balducci","year":"2007","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0100","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1249\/MSS.0b013e3181b3b16d","article-title":"Low-intensity exercise reduces the prevalence of hyperglycemia in type 2 diabetes","volume":"42","author":"Manders","year":"2010","journal-title":"Med Sci Sports Exerc"},{"key":"10.4158\/CS-2017-0153_bb0105","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1007\/s00125-009-1354-3","article-title":"Continuous low- to moderate-intensity exercise training is as effective as moderate- to high-intensity exercise training at lowering blood hba(1c) in obese type 2 diabetes patients","volume":"52","author":"Hansen","year":"2009","journal-title":"Diabetologia"},{"key":"10.4158\/CS-2017-0153_bb0110","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1249\/01.mss.0000235352.09061.1d","article-title":"Influence of acute exercise on hyperglycemia in insulin-treated type 2 diabetes","volume":"38","author":"Praet","year":"2006","journal-title":"Med Sci Sports Exerc"},{"key":"10.4158\/CS-2017-0153_bb0115","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.2337\/dc07-0183","article-title":"Exercise training improves glycemic control in long-standing insulin-treated type 2 diabetic patients","volume":"30","author":"De Feyter","year":"2007","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0120","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1001\/jama.2010.1710","article-title":"Effects of aerobic and resistance training on hemoglobin a1c levels in patients with type 2 diabetes: A randomized controlled trial &lsqb;erratum in JAMA. 2011;305:892]","volume":"304","author":"Church","year":"2010","journal-title":"JAMA"},{"key":"10.4158\/CS-2017-0153_bb0125","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1001\/archinternmed.2010.380","article-title":"Effect of an intensive exercise intervention strategy on modifiable cardiovascular risk factors in subjects with type 2 diabetes mellitus: A randomized controlled trial: The italian diabetes and exercise study (IDES)","volume":"170","author":"Balducci","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.4158\/CS-2017-0153_bb0130","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cger.2014.09.002","article-title":"Falls risk in older adults with type 2 diabetes","volume":"31","author":"Vinik","year":"2015","journal-title":"Clin Geriatr Med"},{"key":"10.4158\/CS-2017-0153_bb0135","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.2337\/dc10-1548","article-title":"Exercise and type 2 diabetes: The American College of Sports Medicine and the American Diabetes Association: Joint position statement executive summary","volume":"33","author":"Colberg","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0140","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jcjd.2013.02.060","article-title":"Inadequate sleep as a contributor to obesity and type 2 diabetes","volume":"37","author":"McNeil","year":"2013","journal-title":"Can J Diabetes"},{"key":"10.4158\/CS-2017-0153_bb0145","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1093\/eurheartj\/ehr007","article-title":"Sleep duration predicts cardiovascular outcomes: A systematic review and meta-analysis of prospective studies","volume":"32","author":"Cappuccio","year":"2011","journal-title":"Eur Heart J"},{"key":"10.4158\/CS-2017-0153_bb0150","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1093\/aje\/kwj280","article-title":"Association between reduced sleep and weight gain in women","volume":"164","author":"Patel","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.4158\/CS-2017-0153_bb0155","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1093\/sleep\/29.8.1009","article-title":"Association of usual sleep duration with hypertension: The Sleep Heart Health Study","volume":"29","author":"Gottlieb","year":"2006","journal-title":"Sleep"},{"key":"10.4158\/CS-2017-0153_bb0160","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/oby.2007.512","article-title":"Short sleep duration is associated with reduced leptin levels and increased adiposity: Results from the Quebec family study","volume":"15","author":"Chaput","year":"2007","journal-title":"Obesity (Silver Spring)"},{"key":"10.4158\/CS-2017-0153_bb0165","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archinte.163.2.205","article-title":"A prospective study of sleep duration and coronary heart disease in women","volume":"163","author":"Ayas","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.4158\/CS-2017-0153_bb0170","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1164\/ajrccm.164.11.2102028","article-title":"Role of snoring and daytime sleepiness in occupational accidents","volume":"164","author":"Lindberg","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.4158\/CS-2017-0153_bb0175","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/sleep\/32.6.772","article-title":"Polysomnographic and health-related quality of life correlates of restless legs syndrome in the Sleep Heart Health Study","volume":"32","author":"Winkelman","year":"2009","journal-title":"Sleep"},{"key":"10.4158\/CS-2017-0153_bb0180","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/oby.2000.31","article-title":"Prevalence of sleep apnea and electrocardiographic disturbances in morbidly obese patients","volume":"8","author":"Valencia-Flores","year":"2000","journal-title":"Obes Res"},{"key":"10.4158\/CS-2017-0153_bb0185","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2337\/diacare.24.6.1069","article-title":"The prevalence of comorbid depression in adults with diabetes: A meta-analysis","volume":"24","author":"Anderson","year":"2001","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0190","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2190\/KLGD-4H8D-4RYL-TWQ8","article-title":"Anxiety and poor glycemic control: A meta-analytic review of the literature","volume":"32","author":"Anderson","year":"2002","journal-title":"Int J Psychiatry Med"},{"key":"10.4158\/CS-2017-0153_bb0195","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2337\/dc09-1519","article-title":"Identifying psychosocial interventions that improve both physical and mental health in patients with diabetes: A systematic review and meta-analysis","volume":"33","author":"Harkness","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0200","doi-asserted-by":"crossref","first-page":"977","DOI":"10.4158\/EP14280.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the 2014 advanced framework for a new diagnosis of obesity as a chronic disease","volume":"20","author":"Garvey","year":"2014","journal-title":"Endocr Pract"},{"key":"10.4158\/CS-2017-0153_bb0205","doi-asserted-by":"crossref","first-page":"642","DOI":"10.4158\/EP12160.PS","article-title":"American Association of Clinical Endocrinologists' position statement on obesity and obesity medicine","volume":"18","author":"Mechanick","year":"2012","journal-title":"Endocrine Pract"},{"issue":"Suppl 3","key":"10.4158\/CS-2017-0153_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP161365.GL","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity","volume":"22","author":"Garvey","year":"2016","journal-title":"Endocr Pract"},{"key":"10.4158\/CS-2017-0153_bb0215","doi-asserted-by":"crossref","first-page":"864","DOI":"10.4158\/EP13263.RA","article-title":"New tools for weight-loss therapy enable a more robust medical model for obesity treatment: Rationale for a complications-centric approach","volume":"19","author":"Garvey","year":"2013","journal-title":"Endocr Pract"},{"key":"10.4158\/CS-2017-0153_bb0220","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1161\/CIRCULATIONAHA.111.026567","article-title":"Medical therapy for the patient with obesity","volume":"125","author":"Bray","year":"2012","journal-title":"Circulation"},{"key":"10.4158\/CS-2017-0153_bb0225","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/01.CIR.0000115514.44135.A8","article-title":"Clinical importance of obesity versus the metabolic syndrome in cardiovascular risk in women: A report from the Women's Ischemia Syndrome Evaluation (WISE) study","volume":"109","author":"Kip","year":"2004","journal-title":"Circulation"},{"key":"10.4158\/CS-2017-0153_bb0230","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/S0140-6736(05)67663-5","article-title":"Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: A case-control study","volume":"366","author":"Yusuf","year":"2005","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb0235","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/ajcn\/80.6.1461","article-title":"Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: A systematic review of randomized clinical trials","volume":"80","author":"Hutton","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"10.4158\/CS-2017-0153_bb0240","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"Xenical in the prevention of diabetes in obese subjects (xendos) study: A randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients &lsqb;erratum in Diabetes Care. 2004;27:856]","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0245","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1056\/NEJMoa0909809","article-title":"Multicenter, placebo-controlled trial of lorcaserin for weight management","volume":"363","author":"Smith","year":"2010","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0250","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/oby.2012.66","article-title":"Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: The BLOOM-DM study","volume":"20","author":"O'Neil","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"10.4158\/CS-2017-0153_bb0255","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1210\/jc.2011-1256","article-title":"A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: The BLOSSOM trial","volume":"96","author":"Fidler","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/CS-2017-0153_bb0260","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3945\/ajcn.111.024927","article-title":"Two-year sustained weight loss and metabolic benefits with controlled-release phentermine\/topiramate in obese and overweight adults (SEQUEL): A randomized, placebo-controlled, phase 3 extension study","volume":"95","author":"Garvey","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"10.4158\/CS-2017-0153_bb0265","doi-asserted-by":"crossref","first-page":"912","DOI":"10.2337\/dc13-1518","article-title":"Prevention of type 2 diabetes in subjects with prediabetes and metabolic syndrome treated with phentermine and topiramate extended release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0270","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/oby.2011.330","article-title":"Controlled-release phentermine\/topiramate in severely obese adults: A randomized controlled trial (EQUIP)","volume":"20","author":"Allison","year":"2012","journal-title":"Obesity (Silver Spring)"},{"key":"10.4158\/CS-2017-0153_bb0275","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S0140-6736(11)60205-5","article-title":"Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): A randomised, placebo-controlled, phase 3 trial","volume":"377","author":"Gadde","year":"2011","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb0280","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.2337\/dc14-0930","article-title":"Weight-loss therapy in type 2 diabetes: Effects of phentermine and topiramate extended-release","volume":"37","author":"Garvey","year":"2014","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0285","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone sr\/bupropion sr on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.4158\/CS-2017-0153_bb0290","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.2337\/dc13-0234","article-title":"Effects of naltrexone sustained-release\/bupropion sustained-release combination therapy on body weight and glycemic parameters in over-weight and obese patients with type 2 diabetes","volume":"36","author":"Hollander","year":"2013","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0295","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: The COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"10.4158\/CS-2017-0153_bb0300","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb0305","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"key":"10.4158\/CS-2017-0153_bb0310","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int J Obes (Lond)"},{"key":"10.4158\/CS-2017-0153_bb0315","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb0320","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0325","doi-asserted-by":"crossref","first-page":"337","DOI":"10.4158\/EP12437.GL","volume":"19","author":"Mechanick","year":"2013","journal-title":"Endocr Pract"},{"key":"10.4158\/CS-2017-0153_bb0330","doi-asserted-by":"crossref","first-page":"933","DOI":"10.4158\/EP.14.7.933","article-title":"Diagnosis and management of prediabetes in the continuum of hyperglycemia: When do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists","volume":"14","author":"Garber","year":"2008","journal-title":"Endocr Pract"},{"key":"10.4158\/CS-2017-0153_bb0335","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0340","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":"Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial","volume":"290","author":"Chiasson","year":"2003","journal-title":"JAMA"},{"key":"10.4158\/CS-2017-0153_bb0345","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/S0140-6736(02)08905-5","article-title":"Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial","volume":"359","author":"Chiasson","year":"2002","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb0350","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1016\/S0140-6736(09)61457-4","article-title":"10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study &lsqb;erratum in Lancet. 2009;374:2054]","volume":"374","author":"Diabetes Prevention Program Research Group","year":"2009","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb0355","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1016\/S0140-6736(06)69420-8","article-title":"Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial &lsqb;erratum in Lancet. 2006:368:1770]","volume":"368","author":"DREAM (Diabetes REduction Assessment with rampipril and rosiglitazone Medication) Trial Investigators","year":"2006","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb0360","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.2337\/diabetes.54.4.1150","article-title":"Prevention of type 2 diabetes with troglitazone in the diabetes prevention program","volume":"54","author":"Knowler","year":"2005","journal-title":"Diabetes"},{"key":"10.4158\/CS-2017-0153_bb0365","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"364","author":"DeFronzo","year":"2011","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0370","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macrovascular events): A randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb0375","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0380","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.2337\/dc13-0354","article-title":"Benefits of liraglutide treatment in overweight and obese older individuals with prediabetes","volume":"36","author":"Kim","year":"2013","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0385","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc09-1203","article-title":"Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes","volume":"33","author":"Rosenstock","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0390","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"ADVANCE Collaborative Group","year":"2008","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0395","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(10)60576-4","article-title":"Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: An analysis of the ACCORD randomised trial","volume":"376","author":"Ismail-Beigi","year":"2010","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb0400","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1001288","article-title":"Effects of medical therapies on retinopathy progression in type 2 diabetes","volume":"363","author":"ACCORD Study Group, ACCORD Eye Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0405","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Action to Control Cardiovascular Risk in Diabetes Study Group","year":"2008","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0410","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2337\/dc09-1278","article-title":"Epidemiologic relationships between a1c and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial","volume":"33","author":"Riddle","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0415","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Veterans Affairs Diabetes Trial Investigators","year":"2009","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0420","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.2337\/dc10-0125","article-title":"Effects of cardiac autonomic dysfunction on mortality risk in the action to control cardiovascular risk in diabetes (ACCORD) trial","volume":"33","author":"Pop-Busui","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0425","doi-asserted-by":"crossref","first-page":"4802","DOI":"10.1210\/jc.2010-0892","article-title":"The approach to the management of the patient with neuropathic pain","volume":"95","author":"Vinik","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/CS-2017-0153_bb0430","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa1414266","article-title":"Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes","volume":"372","author":"Hayward","year":"2015","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0435","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes","volume":"364","author":"ACCORD Study Group","year":"2011","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0440","doi-asserted-by":"crossref","first-page":"b4909","DOI":"10.1136\/bmj.b4909","article-title":"The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: Retrospective epidemiological analysis of the ACCORD study","volume":"340","author":"Bonds","year":"2010","journal-title":"BMJ"},{"key":"10.4158\/CS-2017-0153_bb0445","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1056\/NEJM199602293340906","article-title":"Metformin","volume":"334","author":"Bailey","year":"1996","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0450","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa066224","article-title":"Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy","volume":"355","author":"Kahn","year":"2006","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0455","doi-asserted-by":"crossref","first-page":"601","DOI":"10.7326\/0003-4819-157-9-201211060-00003","article-title":"Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: A cohort study","volume":"157","author":"Roumie","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.4158\/CS-2017-0153_bb0460","series-title":"Glucophage (metformin hydrochloride) tablets","year":"2017"},{"key":"10.4158\/CS-2017-0153_bb0465","series-title":"FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function","author":"U.S. Food and Drug Administration","year":"2016"},{"key":"10.4158\/CS-2017-0153_bb0470","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes CKD Work Group","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.4158\/CS-2017-0153_bb0475","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.2337\/dc10-2361","article-title":"Use of metformin in the setting of mild-to-moderate renal insufficiency","volume":"34","author":"Lipska","year":"2011","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0480","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2337\/dc11-1582","article-title":"Association of biochemical B12 deficiency with metformin therapy and vitamin B12 supplements: The National Health and Nutrition Examination Survey, 1999\u20132006","volume":"35","author":"Reinstatler","year":"2012","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0485","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1111\/j.1532-5415.2012.03998.x","article-title":"Relationship between vitamin b12 and sensory and motor peripheral nerve function in older adults","volume":"60","author":"Leishear","year":"2012","journal-title":"J Am Geriatr Soc"},{"key":"10.4158\/CS-2017-0153_bb0490","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2337\/dc09-0606","article-title":"Association of metformin, elevated homocysteine, and methylmalonic acid levels and clinically worsened diabetic peripheral neuropathy","volume":"33","author":"Wile","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0495","doi-asserted-by":"crossref","first-page":"253","DOI":"10.4103\/0022-3859.123143","article-title":"Association of B12 deficiency and clinical neuropathy with metformin use in type 2 diabetes patients","volume":"59","author":"Singh","year":"2013","journal-title":"J Postgrad Med"},{"key":"10.4158\/CS-2017-0153_bb0500","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1463-1326.2012.01603.x","article-title":"Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis","volume":"14","author":"Deacon","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/CS-2017-0153_bb0505","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clinthera.2014.11.008","article-title":"Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: A systematic review and network meta-analysis","volume":"37","author":"Sun","year":"2015","journal-title":"Clin Ther"},{"key":"10.4158\/CS-2017-0153_bb0510","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0515","series-title":"Victoza (liraglutide rDNA origin) injection prescribing information","year":"2017"},{"key":"10.4158\/CS-2017-0153_bb0520","doi-asserted-by":"crossref","first-page":"72","DOI":"10.4161\/isl.2.2.10582","article-title":"Facilitation of \u03b2-cell k(atp) channel sulfonylurea sensitivity by a cAMP analog selective for the cAMP-regulated guanine nucleotide exchange factor Epac","volume":"2","author":"Leech","year":"2010","journal-title":"Islets"},{"key":"10.4158\/CS-2017-0153_bb0525","first-page":"61","article-title":"The treatment of type 2 diabetes in the presence of renal impairment: What we should know about newer therapies","volume":"8","author":"Davies","year":"2016","journal-title":"Clin Pharmacol"},{"key":"10.4158\/CS-2017-0153_bb0530","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1056\/NEJMp1001578","article-title":"Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy","volume":"362","author":"Parks","year":"2010","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0535","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0540","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0545","series-title":"Jardiance (empagliflozin) prescribing information","year":"2016"},{"key":"10.4158\/CS-2017-0153_bb0550","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/1753-0407.12065","article-title":"Sodium glucose transporter 2 inhibition: A new approach to diabetes treatment","volume":"5","author":"Bloomgarden","year":"2013","journal-title":"J Diabetes"},{"key":"10.4158\/CS-2017-0153_bb0555","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.2337\/dc15-0843","article-title":"Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition","volume":"38","author":"Peters","year":"2015","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0560","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2147\/DDDT.S50773","article-title":"Update on developments with SGLT2 inhibitors in the management of type 2 diabetes","volume":"8","author":"Nauck","year":"2014","journal-title":"Drug Des Devel Ther"},{"key":"10.4158\/CS-2017-0153_bb0565","series-title":"Invokana (canagliflozin) prescribing information","year":"2017"},{"key":"10.4158\/CS-2017-0153_bb0570","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00125-017-4301-8","article-title":"SGLT2 inhibitors and diabetic ketoacidosis: Data from the fda adverse event reporting system","volume":"60","author":"Fadini","year":"2017","journal-title":"Diabetologia"},{"key":"10.4158\/CS-2017-0153_bb0575","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrendo.2017.77","article-title":"Diabetes: SGLT2 inhibitors and diabetic ketoacidosis - a growing concern","volume":"13","author":"Umpierrez","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"10.4158\/CS-2017-0153_bb0580","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.2337\/dc15-1251","article-title":"Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program","volume":"38","author":"Erondu","year":"2015","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0585","doi-asserted-by":"crossref","first-page":"753","DOI":"10.4158\/EP161292.PS","article-title":"American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoacidosis","volume":"22","author":"Handelsman","year":"2016","journal-title":"Endocr Pract"},{"key":"10.4158\/CS-2017-0153_bb0590","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1463-1326.2010.01306.x","article-title":"Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: A comparative review","volume":"13","author":"Deacon","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/CS-2017-0153_bb0595","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.beem.2009.03.003","article-title":"Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events","volume":"23","author":"Ahr\u00e9n","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.4158\/CS-2017-0153_bb0600","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White","year":"2013","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0605","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica","year":"2013","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0610","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0615","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1016\/S0140-6736(14)62225-X","article-title":"Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in examine: A multicentre, randomised, double-blind trial","volume":"385","author":"Zannad","year":"2015","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb0620","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1161\/CIRCULATIONAHA.114.010389","article-title":"Heart failure, saxagliptin, and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomized trial","volume":"130","author":"Scirica","year":"2014","journal-title":"Circulation"},{"key":"10.4158\/CS-2017-0153_bb0625","doi-asserted-by":"crossref","first-page":"773","DOI":"10.2337\/db09-9028","article-title":"From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus","volume":"58","author":"DeFronzo","year":"2009","journal-title":"Diabetes"},{"key":"10.4158\/CS-2017-0153_bb0630","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1001\/jama.298.10.1180","article-title":"Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: A meta-analysis of randomized trials","volume":"298","author":"Lincoff","year":"2007","journal-title":"JAMA"},{"key":"10.4158\/CS-2017-0153_bb0635","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0140-6736(09)60953-3","article-title":"Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial","volume":"373","author":"Home","year":"2009","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb0640","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1056\/NEJMp1309610","article-title":"The cardiovascular safety of diabetes drugs--insights from the rosiglitazone experience","volume":"369","author":"Hiatt","year":"2013","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0645","doi-asserted-by":"crossref","first-page":"386","DOI":"10.7326\/0003-4819-147-6-200709180-00178","article-title":"Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes mellitus &lsqb;erratum in Ann Intern Med. 2007;147:887]","volume":"147","author":"Bolen","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.4158\/CS-2017-0153_bb0650","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2337\/dc07-2270","article-title":"Rosiglitazone-associated fractures in type 2 diabetes: An analysis from a diabetes outcome progression trial (ADOPT)","volume":"31","author":"Kahn","year":"2008","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0655","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1210\/jc.2005-2226","article-title":"Thiazolidinedione use and bone loss in older diabetic adults","volume":"91","author":"Schwartz","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/CS-2017-0153_bb0660","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1111\/dme.12144","article-title":"Pioglitazone and risk of bladder cancer: A meta-analysis of controlled studies","volume":"30","author":"Ferwana","year":"2013","journal-title":"Diabet Med"},{"key":"10.4158\/CS-2017-0153_bb0665","first-page":"914","article-title":"Pioglitazone and risk for bone fracture: Safety data from a randomized clinical trial","volume":"102","author":"Viscoli","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/CS-2017-0153_bb0670","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2015.7996","article-title":"Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes","volume":"314","author":"Lewis","year":"2015","journal-title":"JAMA"},{"key":"10.4158\/CS-2017-0153_bb0675","doi-asserted-by":"crossref","first-page":"357","DOI":"10.2147\/DMSO.S28340","article-title":"Critical evaluation of the role of acarbose in the treatment of diabetes: Patient considerations","volume":"5","author":"Rosak","year":"2012","journal-title":"Diabetes Metab Syndr Obes"},{"key":"10.4158\/CS-2017-0153_bb0680","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0195-668X(03)00468-8","article-title":"Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: Meta-analysis of seven long-term studies","volume":"25","author":"Hanefeld","year":"2004","journal-title":"Eur Heart J"},{"key":"10.4158\/CS-2017-0153_bb0685","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1001\/jama.2010.405","article-title":"Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes","volume":"303","author":"Phung","year":"2010","journal-title":"JAMA"},{"key":"10.4158\/CS-2017-0153_bb0690","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/1479164112465442","article-title":"Association of sulphonylurea treatment with all-cause and cardiovascular mortality: A systematic review and meta-analysis of observational studies","volume":"10","author":"Forst","year":"2013","journal-title":"Diab Vasc Dis Res"},{"key":"10.4158\/CS-2017-0153_bb0695","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1463-1326.2009.01181.x","article-title":"Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence","volume":"12","author":"Fonseca","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/CS-2017-0153_bb0700","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2337\/dc11-0064","article-title":"Bromocriptine: A sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes","volume":"34","author":"Defronzo","year":"2011","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0705","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2337\/dc09-2009","article-title":"Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes","volume":"33","author":"Gaziano","year":"2010","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0710","doi-asserted-by":"crossref","first-page":"e002279","DOI":"10.1161\/JAHA.112.002279","article-title":"Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjects","volume":"1","author":"Gaziano","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"10.4158\/CS-2017-0153_bb0715","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.2337\/dc11-1928","article-title":"Sequential intensification of metformin treatment in type 2 diabetes with liraglutide followed by randomized addition of basal insulin prompted by A1C targets","volume":"35","author":"Devries","year":"2012","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0720","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.jdiacomp.2013.04.008","article-title":"One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target","volume":"27","author":"Rosenstock","year":"2013","journal-title":"J Diabetes Complications"},{"key":"10.4158\/CS-2017-0153_bb0725","doi-asserted-by":"crossref","first-page":"3080","DOI":"10.2337\/diacare.26.11.3080","article-title":"The treat-to-target trial: Randomized addition of glargine or human nph insulin to oral therapy of type 2 diabetic patients","volume":"26","author":"Insulin Glargine Study 4002 Study Investigators","year":"2003","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0730","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.2337\/dc05-1365","article-title":"A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes","volume":"29","author":"Hermansen","year":"2006","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0735","doi-asserted-by":"crossref","first-page":"950","DOI":"10.2337\/diacare.28.4.950","article-title":"Reduced hypoglycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human nph insulin in type 2 diabetes","volume":"28","author":"Rosenstock","year":"2005","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0740","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.diabres.2008.04.007","article-title":"Long-acting insulin analogues versus nph human insulin in type 2 diabetes: A meta-analysis","volume":"81","author":"Monami","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"10.4158\/CS-2017-0153_bb0745","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1463-1326.2010.01232.x","article-title":"Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine","volume":"12","author":"Home","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/CS-2017-0153_bb0750","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1615692","article-title":"Efficacy and safety of degludec versus glargine in type 2 diabetes","volume":"377","author":"Marso","year":"2017","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0755","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1517\/17425255.2015.1058779","article-title":"Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine","volume":"11","author":"Heise","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.4158\/CS-2017-0153_bb0760","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/dom.12938","article-title":"Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 u\/ml in type 1 diabetes","volume":"19","author":"Heise","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/CS-2017-0153_bb0765","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2337\/dc14-0006","article-title":"New insulin glargine 300 units \u00b7 mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 units \u00b7 mL-1","volume":"38","author":"Becker","year":"2015","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0770","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.2337\/dc14-0991","article-title":"New insulin glargine 300 units\/mL versus glargine 100 units\/mL in people with type 2 diabetes using basal and mealtime insulin: Glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)","volume":"37","author":"Riddle","year":"2014","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0775","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(12)60205-0","article-title":"Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN basal-bolus type 2): A phase 3, randomised, open-label, treat-to-target non-inferiority trial","volume":"379","author":"Garber","year":"2012","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb0780","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.2337\/dc12-2329","volume":"36","author":"Gough","year":"2013","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0785","doi-asserted-by":"crossref","first-page":"858","DOI":"10.2337\/dc12-1668","volume":"36","author":"Meneghini","year":"2013","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0790","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.2337\/dc12-1205","article-title":"Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)","volume":"35","author":"Zinman","year":"2012","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0795","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2337\/diacare.28.2.254","article-title":"Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes","volume":"28","author":"Janka","year":"2005","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0800","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2165\/11535380-000000000-00000","article-title":"Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin alone in patients with type 2 diabetes mellitus in canada","volume":"8","author":"Tunis","year":"2010","journal-title":"Appl Health Econ Health Policy"},{"key":"10.4158\/CS-2017-0153_bb0805","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1056\/NEJM199211123272005","article-title":"Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus","volume":"327","author":"Yki-J\u00e4rvinen","year":"1992","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0810","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-156-6-201203200-00003","article-title":"Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: A randomized trial","volume":"156","author":"Wilding","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.4158\/CS-2017-0153_bb0815","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0820","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1185\/03007995.2012.665046","article-title":"Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin","volume":"28","author":"Barnett","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.4158\/CS-2017-0153_bb0825","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7326\/0003-4819-154-2-201101180-00300","article-title":"Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: A randomized, controlled trial","volume":"154","author":"Buse","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.4158\/CS-2017-0153_bb0830","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): A randomised controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"key":"10.4158\/CS-2017-0153_bb0835","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/j.1463-1326.2009.01173.x","article-title":"Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes","volume":"12","author":"Vilsboll","year":"2010","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/CS-2017-0153_bb0840","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1056\/NEJMra040832","article-title":"Insulin analogues","volume":"352","author":"Hirsch","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0845","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1001\/jama.2017.6939","article-title":"Human insulin for type 2 diabetes: An effective, less-expensive option","volume":"318","author":"Lipska","year":"2017","journal-title":"JAMA"},{"key":"10.4158\/CS-2017-0153_bb0850","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1177\/193229681300700323","article-title":"Common standards of basal insulin titration in type 2 diabetes","volume":"7","author":"Arnolds","year":"2013","journal-title":"J Diabetes Sci Technol"},{"key":"10.4158\/CS-2017-0153_bb0855","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1463-1326.2011.01459.x","article-title":"Effects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: A 6-month \u2018proof-of-concept\u2019 study","volume":"13","author":"Owens","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/CS-2017-0153_bb0860","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/j.1463-1326.2008.00967.x","article-title":"Introducing a simplified approach to insulin therapy in type 2 diabetes: A comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs","volume":"10","author":"Orals Plus Apidra and LANTUS (OPAL) study group","year":"2008","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/CS-2017-0153_bb0865","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ecl.2012.03.004","article-title":"Insulin therapy in type 2 diabetes mellitus","volume":"41","author":"Leahy","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.4158\/CS-2017-0153_bb0870","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1185\/03007991003634759","article-title":"Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs","volume":"26","author":"Peyrot","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.4158\/CS-2017-0153_bb0875","doi-asserted-by":"crossref","first-page":"330","DOI":"10.2337\/diacare.25.2.330","article-title":"Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57)","volume":"25","author":"Wright","year":"2002","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0880","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1007\/s00125-007-0599-y","article-title":"Risk of hypoglycaemia in types 1 and 2 diabetes: Effects of treatment modalities and their duration","volume":"50","author":"UK Hypoglycaemia Study Group","year":"2007","journal-title":"Diabetologia"},{"key":"10.4158\/CS-2017-0153_bb0885","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1001\/jama.289.17.2254","article-title":"Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review","volume":"289","author":"DeWitt","year":"2003","journal-title":"JAMA"},{"key":"10.4158\/CS-2017-0153_bb0890","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4158\/EP13005.RA","article-title":"Hypoglycemia: Minimizing its impact in type 2 diabetes","volume":"19","author":"Moghissi","year":"2013","journal-title":"Endocr Pract"},{"key":"10.4158\/CS-2017-0153_bb0895","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1177\/1932296815581052","article-title":"Hypoglycemia in type 2 diabetes--more common than you think: A continuous glucose monitoring study","volume":"9","author":"Gehlaut","year":"2015","journal-title":"J Diabetes Sci Technol"},{"key":"10.4158\/CS-2017-0153_bb0900","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","article-title":"Severe hypoglycemia and risks of vascular events and death","volume":"363","author":"Zoungas","year":"2010","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0905","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/j.amjmed.2011.08.008","article-title":"Death during intensive glycemic therapy of diabetes: Mechanisms and implications","volume":"124","author":"Cryer","year":"2011","journal-title":"Am J Med"},{"key":"10.4158\/CS-2017-0153_bb0910","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1089\/dia.2017.0090","article-title":"Continuous glucose monitoring with multiple daily insulin treatment: Outcome studies","volume":"19","author":"McGill","year":"2017","journal-title":"Diabetes Technol Ther"},{"key":"10.4158\/CS-2017-0153_bb0915","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1161\/CIRCULATIONAHA.110.016337","article-title":"Blood pressure targets in subjects with type 2 diabetes mellitus\/impaired fasting glucose: Observations from traditional and bayesian random-effects meta-analyses of randomized trials","volume":"123","author":"Bangalore","year":"2011","journal-title":"Circulation"},{"key":"10.4158\/CS-2017-0153_bb0920","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1001\/archinternmed.2012.3147","article-title":"Intensive and standard blood pressure targets in patients with type 2 diabetes mellitus: Systematic review and meta-analysis","volume":"172","author":"McBrien","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.4158\/CS-2017-0153_bb0925","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1097\/HJH.0b013e32832d7370","article-title":"Prognostic value of blood pressure in patients with high vascular risk in the ongoing telmisartan alone and in combination with ramipril global endpoint trial study","volume":"27","author":"Sleight","year":"2009","journal-title":"J Hypertens"},{"key":"10.4158\/CS-2017-0153_bb0930","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0935","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.1997.03540440058033","article-title":"Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials","volume":"277","author":"Whelton","year":"1997","journal-title":"JAMA"},{"key":"10.4158\/CS-2017-0153_bb0940","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.2337\/diacare.28.12.2823","article-title":"Beneficial effects of a dietary approaches to stop hypertension eating plan on features of the metabolic syndrome","volume":"28","author":"Azadbakht","year":"2005","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0945","doi-asserted-by":"crossref","first-page":"162","DOI":"10.2337\/dc07-9917","article-title":"Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetes Association","volume":"30","author":"Buse","year":"2007","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0950","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/archinternmed.2009.56","article-title":"Consistency with the DASH diet and incidence of heart failure","volume":"169","author":"Levitan","year":"2009","journal-title":"Arch Intern Med"},{"key":"10.4158\/CS-2017-0153_bb0955","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.2337\/dc09-0228","article-title":"Adherence to the dash diet is inversely associated with incidence of type 2 diabetes: The insulin resistance atherosclerosis study","volume":"32","author":"Liese","year":"2009","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb0960","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJM200101043440101","article-title":"Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-Sodium Collaborative Research Group","volume":"344","author":"Sacks","year":"2001","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb0965","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.7326\/0003-4819-135-12-200112180-00005","article-title":"Effects of diet and sodium intake on blood pressure: Subgroup analysis of the DASH-sodium trial","volume":"135","author":"Vollmer","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.4158\/CS-2017-0153_bb0970","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ypmed.2003.11.027","article-title":"A meta-analysis of alcohol consumption and the risk of 15 diseases","volume":"38","author":"Corrao","year":"2004","journal-title":"Prev Med"},{"key":"10.4158\/CS-2017-0153_bb0975","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1161\/CIRCULATIONAHA.109.865840","article-title":"Cardiovascular and overall mortality risk in relation to alcohol consumption in patients with cardiovascular disease","volume":"121","author":"Costanzo","year":"2010","journal-title":"Circulation"},{"key":"10.4158\/CS-2017-0153_bb0980","series-title":"ACSM's Resource Manual for Guidelines for Exercise Testing and Prescription","first-page":"285","article-title":"Exercise and hypertension","author":"Stewart","year":"2001"},{"key":"10.4158\/CS-2017-0153_bb0985","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"key":"10.4158\/CS-2017-0153_bb0990","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the hope study and micro-hope substudy. &lsqb;erratum in Lancet. 2000;356:860]","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb0995","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1016\/S0140-6736(98)04311-6","article-title":"Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group","volume":"351","author":"Hansson","year":"1998","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb1000","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb1005","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1001\/archinte.165.8.936","article-title":"Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"165","author":"Rahman","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.4158\/CS-2017-0153_bb1010","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","article-title":"Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: A randomised controlled trial","volume":"372","author":"Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators","year":"2008","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb1015","doi-asserted-by":"crossref","first-page":"888","DOI":"10.2337\/diacare.23.7.888","article-title":"Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes","volume":"23","author":"Pahor","year":"2000","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb1020","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa0806182","article-title":"Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients","volume":"359","author":"Jamerson","year":"2008","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb1025","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb1030","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb1035","first-page":"e6","article-title":"Heart disease and stroke statistics--2013 update: A report from the American Heart Association","volume":"127","author":"Go","year":"2013","journal-title":"Circulation"},{"key":"10.4158\/CS-2017-0153_bb1040","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.4158\/CS-2017-0153_bb1045","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: A meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.4158\/CS-2017-0153_bb1050","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb1055","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.atherosclerosis.2014.05.914","article-title":"Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets","volume":"235","author":"Toth","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.4158\/CS-2017-0153_bb1060","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jacl.2011.02.001","article-title":"Clinical implications of discordance between low-density lipoprotein cholesterol and particle number","volume":"5","author":"Otvos","year":"2011","journal-title":"J Clin Lipidol"},{"key":"10.4158\/CS-2017-0153_bb1065","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb1070","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb1075","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb1080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: A meta-analysis","volume":"371","author":"Cholesterol Treatment Trialists (CTT) Collaborators","year":"2008","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb1085","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/000331970305400607","article-title":"Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus","volume":"54","author":"Athyros","year":"2003","journal-title":"Angiology"},{"key":"10.4158\/CS-2017-0153_bb1090","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial","volume":"360","author":"Heart Protection Study Collaborative Group","year":"2002","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb1095","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1093\/eurheartj\/ehl220","article-title":"Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur Heart J"},{"key":"10.4158\/CS-2017-0153_bb1100","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.292.11.1307","article-title":"Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial","volume":"292","author":"de Lemos","year":"2004","journal-title":"JAMA"},{"key":"10.4158\/CS-2017-0153_bb1105","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.jacc.2005.02.080","article-title":"Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg\/dl and c-reactive protein <2 mg\/l: An analysis of the PROVE-IT TIMI-22 trial","volume":"45","author":"Ridker","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.4158\/CS-2017-0153_bb1110","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2337\/dc05-2465","article-title":"Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study","volume":"29","author":"Shepherd","year":"2006","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb1115","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.4158\/CS-2017-0153_bb1120","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jacl.2007.12.006","article-title":"Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: Implications for clinical practice","volume":"2","author":"Sniderman","year":"2008","journal-title":"J Clin Lipidol"},{"key":"10.4158\/CS-2017-0153_bb1125","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patient--the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.4158\/CS-2017-0153_bb1130","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/j.1365-2362.2009.02163.x","article-title":"Ezetimibe improves postprandial hyperlipidaemia in patients with type IIb hyperlipidaemia","volume":"39","author":"Masuda","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.4158\/CS-2017-0153_bb1135","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1316222","article-title":"A 52-week placebo-controlled trial of evolocumab in hyperlipidemia","volume":"370","author":"Blom","year":"2014","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb1140","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb1145","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb1150","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1515\/cclm-2013-0358","article-title":"Recent advances in physiological lipoprotein metabolism","volume":"52","author":"Ramasamy","year":"2014","journal-title":"Clin Chem Lab Med"},{"key":"10.4158\/CS-2017-0153_bb1155","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","article-title":"Safety and efficacy of anti-PCSK9 antibodies: A meta-analysis of 25 randomized, controlled trials","volume":"13","author":"Zhang","year":"2015","journal-title":"BMC Med"},{"key":"10.4158\/CS-2017-0153_bb1160","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ejphar.2015.03.099","article-title":"PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia","volume":"763","author":"Verbeek","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.4158\/CS-2017-0153_bb1165","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1210\/jc.2015-1520","article-title":"Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I Randomized Trial","volume":"100","author":"Bays","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/CS-2017-0153_bb1170","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb1175","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb1180","unstructured":"ColhounHM, GinsbergHN, LeiterLA, et al. Efficacy and safety of alirocumab in individuals with diabetes: Analyses from the ODYSSEY Long Term study. In: Program of the 51st Annual Meeting of the European Association for the Study of Diabetes. September 14\u201318, 2015; Stockholm, Sweden. Abstract."},{"key":"10.4158\/CS-2017-0153_bb1185","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1001\/archinte.159.16.1893","article-title":"Colesevelam hydrochloride (cholestagel): A new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects","volume":"159","author":"Davidson","year":"1999","journal-title":"Arch Intern Med"},{"issue":"Suppl 2","key":"10.4158\/CS-2017-0153_bb1190","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.2337\/dc11-s237","article-title":"Role of bile acid sequestrants in the treatment of type 2 diabetes","volume":"34","author":"Handelsman","year":"2011","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb1195","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.atherosclerosis.2008.09.026","article-title":"Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes","volume":"204","author":"Rosenson","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.4158\/CS-2017-0153_bb1200","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1097\/FJC.0b013e31823a109f","article-title":"Efficacy of colesevelam on lowering glycemia and lipids","volume":"59","author":"Aggarwal","year":"2012","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.4158\/CS-2017-0153_bb1205","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb1210","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb1215","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"ACCORD Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb1220","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.CIR.85.1.37","article-title":"Joint effects of serum triglyceride and ldl cholesterol and hdl cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment","volume":"85","author":"Manninen","year":"1992","journal-title":"Circulation"},{"key":"10.4158\/CS-2017-0153_bb1225","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: A systematic review and meta-analysis","volume":"57","author":"Bruckert","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.4158\/CS-2017-0153_bb1230","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"10.4158\/CS-2017-0153_bb1235","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMc1006407","article-title":"Combination lipid therapy in type 2 diabetes","volume":"363","author":"Sacks","year":"2010","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb1240","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: A meta-analysis","volume":"217","author":"Lee","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.4158\/CS-2017-0153_bb1245","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2796.2005.01528.x","article-title":"Nicotinic acid: The broad-spectrum lipid drug. A 50th anniversary review","volume":"258","author":"Carlson","year":"2005","journal-title":"J Intern Med"},{"key":"10.4158\/CS-2017-0153_bb1250","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1046\/j.1463-1326.2002.00205.x","article-title":"Niacin treatment of the atherogenic lipid profile and Lp(a) in diabetes","volume":"4","author":"Pan","year":"2002","journal-title":"Diabetes Obes Metab"},{"key":"10.4158\/CS-2017-0153_bb1255","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low hdl cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb1260","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"HPS2-THRIVE Collaborative Group","year":"2014","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb1265","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.jacc.2012.10.030","article-title":"The current state of niacin in cardiovascular disease prevention: A systematic review and meta-regression","volume":"61","author":"Lavigne","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.4158\/CS-2017-0153_bb1270","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.amjcard.2004.09.013","article-title":"Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)","volume":"95","author":"Canner","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.4158\/CS-2017-0153_bb1275","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","article-title":"Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis","volume":"369","author":"Yokoyama","year":"2007","journal-title":"Lancet"},{"key":"10.4158\/CS-2017-0153_bb1280","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.atherosclerosis.2009.03.029","article-title":"Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan Epa Lipid Intervention Study (JELIS)","volume":"206","author":"Oikawa","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.4158\/CS-2017-0153_bb1285","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2008.06.003","article-title":"Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)","volume":"200","author":"Saito","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.4158\/CS-2017-0153_bb1290","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1205409","article-title":"n-3 fatty acids in patients with multiple cardiovascular risk factors","volume":"368","author":"Risk and Prevention Study Collaborative Group","year":"2013","journal-title":"N Engl J Med"},{"key":"10.4158\/CS-2017-0153_bb1295","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia","volume":"367","author":"ORIGINS Trial Investigators","year":"2012","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"10.4158\/CS-2017-0153_bb1300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP.18.S1.1","article-title":"American Association of Clinical Endocrinologists' guidelines for management of dyslipidemia and prevention of atherosclerosis","volume":"18","author":"Jellinger","year":"2012","journal-title":"Endocr Pract"},{"key":"10.4158\/CS-2017-0153_bb1305","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/S2213-8587(13)70191-8","article-title":"The polygenic nature of hypertriglyceridaemia: Implications for definition, diagnosis, and management","volume":"2","author":"Hegele","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.4158\/CS-2017-0153_bb1310","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.amjmed.2013.09.018","article-title":"Determining triglyceride reductions needed for clinical impact in severe hypertriglyceridemia","volume":"127","author":"Christian","year":"2014","journal-title":"Am J Med"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2039340X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2039340X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:06:07Z","timestamp":1761516367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2039340X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":261,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1530891X2039340X"],"URL":"https:\/\/doi.org\/10.4158\/cs-2017-0153","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm \u2013 2018 Executive Summary","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/CS-2017-0153","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}